Core Viewpoint - The control transfer of Yiming Pharmaceutical has been completed, with the new owner being Yao Jinbo, the founder of 58.com, marking it as his first A-share listed company [2][3]. Group 1: Company Overview - Yiming Pharmaceutical, with a market value of just over 2 billion, has been relatively unnoticed until now [2]. - The company was listed at the end of 2016, focusing on chronic medications for diabetes and cardiovascular diseases, including products like Yiming Aotianping and Yiming Weidongling [3]. Group 2: Financial Performance - Yiming Pharmaceutical's revenue has stagnated, with 2020 revenue at 600 million and projected revenue of 650 million in 2024, showing a decline of 7.4% in Q1 2025 [3][5]. - The net profit has remained stable at around 30-40 million, with R&D expenses projected to be over 15 million in 2024, indicating limited growth potential for a pharmaceutical company [5]. Group 3: Acquisition Insights - Yao Jinbo's acquisition price of 15.10 CNY per share represents a 24% premium over the last closing price and a 30% premium over the 20-day average price prior to suspension, indicating a strong commitment [2]. - The financials reveal that Yiming Pharmaceutical has a clean balance sheet, with 320 million in cash, 170 million in accounts receivable, and total liabilities under 300 million, suggesting it is a clean shell for potential future operations [6][9]. Group 4: Future Expectations - The share transfer agreement includes performance commitments from the previous controlling shareholder, ensuring revenue of no less than 600 million and net profit of no less than 30 million from 2025 to 2027, which may guide Yao's future plans for the company [11].
姚劲波A股首秀,易明医药一字涨停!壳资源迎价值重估,58赶集要借壳上市?